Harnessing the U.S. Taxpayer to Fight Cancer and Make Profits
From the article:
Rachel Sachs, an associate law professor at Washington University in St. Louis and expert in innovation policy, said the government had every right to seek price concessions. She noted that the government, through Medicare and Medicaid, was effectively buying its inventions back from itself. “The public is paying for the research and to the extent that many people, if not most, will pay through public insurance, we’re paying again,” she said.
Read the full piece!biotechnology health care finance health law policy innovation medicaremedicaid pharmaceuticals regulation research funding